Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The positron emission tomography (PET) radiotracer Pittsburgh Compound-B (PiB) binds with high affinity to beta-pleated sheet aggregates of the amyloid-beta (Abeta) peptide in vitro. The in vivo retention of PiB in brains of people with Alzheimer's disease shows a regional distribution that is very similar to distribution of Abeta deposits observed post-mortem. However, the basis for regional variations in PiB binding in vivo, and the extent to which it binds to different types of Abeta-containing plaques and tau-containing neurofibrillary tangles (NFT), has not been thoroughly investigated. The present study examined 28 clinically diagnosed and autopsy-confirmed Alzheimer's disease subjects, including one Alzheimer's disease subject who had undergone PiB-PET imaging 10 months prior to death, to evaluate region- and substrate-specific binding of the highly fluorescent PiB derivative 6-CN-PiB. These data were then correlated with region-matched Abeta plaque load and peptide levels, [(3)H]PiB binding in vitro, and in vivo PET retention levels. We found that in Alzheimer's disease brain tissue sections, the preponderance of 6-CN-PiB binding is in plaques immunoreactive to either Abeta42 or Abeta40, and to vascular Abeta deposits. 6-CN-PiB labelling was most robust in compact/cored plaques in the prefrontal and temporal cortices. While diffuse plaques, including those in caudate nucleus and presubiculum, were less prominently labelled, amorphous Abeta plaques in the cerebellum were not detectable with 6-CN-PiB. Only a small subset of NFT were 6-CN-PiB positive; these resembled extracellular 'ghost' NFT. In Alzheimer's disease brain tissue homogenates, there was a direct correlation between [(3)H]PiB binding and insoluble Abeta peptide levels. In the Alzheimer's disease subject who underwent PiB-PET prior to death, in vivo PiB retention levels correlated directly with region-matched post-mortem measures of [(3)H]PiB binding, insoluble Abeta peptide levels, 6-CN-PiB- and Abeta plaque load, but not with measures of NFT. These results demonstrate, in a typical Alzheimer's disease brain, that PiB binding is highly selective for insoluble (fibrillar) Abeta deposits, and not for neurofibrillary pathology. The strong direct correlation of in vivo PiB retention with region-matched quantitative analyses of Abeta plaques in the same subject supports the validity of PiB-PET imaging as a method for in vivo evaluation of Abeta plaque burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Fig. 6 Correlations of the in vivo PiB DVR values from the 19 VOIs (six of the 25 VOIs had <70% tissue and were not included in the analysis, see Methods section) on the PET scan with post-mortem quantifications of 6-CN-PiB (A) or Aβ (B) plaque load, neurofibrillary load (C) and [3H]PiB binding (D) in the corresponding 19 tissue cubes from the formalin fixed left hemisphere. In vivo PiB-PET retention (DVR) levels correlate directly with regional post-mortem quantitations of 6-CN-PiB (A) and 6E10 (B) plaque loads as well as in vitro PiB binding (D), but not with AT8 neurofibrillary load (C) in formalin-fixed tissue from the left hemisphere. In fresh-frozen tissue from the right hemisphere of the same Alzheimer's disease subject, there is a significant correlation of both in vitro PiB binding (E) and total insoluble Aβ (Aβ1–40 + Aβ1–42) peptide levels (F) with in vivo PiB-PET retention (DVR) levels.](https://figures.cochat.ai/paper-figures/e33db6b5b74a421cb6ab860a36a812a8/post-mortem-correlates-of-in-vivo-pib-pet-amyloid-imaging-in-a-typical-case-of-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in accordance with the relative resistance of this region to pathology in mouse AD models and AD patients26”
From Transcriptional signature in microglia associated with Aβ plaque phagocytosis (2021) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent amyloid imaging techniques have proved an association with Alzheimer disease pathology235 and may prove useful for evaluating the independent and combined effects of vascular and Alzheimer disease brain injury on cognitive changes during normal aging in the future.”
The cited source says what the claim attributes to it.
In the citing paper
“Imaging-to-autopsy comparison studies have established that amyloid positron emission tomography (PET) is a valid in vivo surrogate for Aβ deposits (in brain parenchyma/vessel walls) [17–24].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“the [11C]-benzothiazole radiotracer, Pittsburgh Compound B (PIB), as well as other tracers, can bind to fibrillar Aβ plaques, allowing for visualization of brain amyloid in individuals during positron emission tomography (PET) (23-25).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 3×
“In this case, the final neuropathological diagnosis by CERAD criteria (Mirra et al., 1991) was ‘definite Alzheimer’s disease’, and the Braak stage (Braak and Braak, 1991b) was V/VI.”
BackgroundResultMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 7×
“…Alzheimer’s disease patients have 2- to 3-fold greater PiB retention on PET scans in brain areas known to have high amounts of fibrillar (i.e. Congo red and thioflavin-S labelled) Ab plaques in Alzheimer’s disease, such as frontal cortex and temporal lobe (Klunk et al., 2004; Price et al., 2005).”
BackgroundInfluentialSelf-citationGauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Simplified Reference Tissue Model for PET Receptor Studies
Lammertsma, A. A., & Hume, S. P. (1996) · NeuroImage · doi:10.1006/nimg.1996.0066 · Cited by 2,021 · cited 1×
“Logan graphical analyses (Logan et al., 1996) were performed for 35–60min (5 points) intervals using input functions derived from cerebellar tissue radioactivity to yield the DVR as the outcome measure (Lammertsma and Hume, 1996).”
MethodIwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774 · cited 1×
“Ab42-containing plaques and Ab42 peptide levels are much more abundant in Alzheimer’s disease brain (Iwatsubo et al., 1994; Naslund et al., 2000), and therefore likely drive the correlation between PiB and total Ab peptide (Ab42 and Ab40 combined) levels as determined in our ELISA assays.”
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514 · cited 1×
“Logan graphical analyses (Logan et al., 1996) were performed for 35–60min (5 points) intervals using input functions derived from cerebellar tissue radioactivity to yield the DVR as the outcome measure (Lammertsma and Hume, 1996).”
Method
Research works printed but not linked: 2
- Braak, 1991, Neuropathological staging of Alzheimer's disease, Acta Neuropath, 82, 239, 10.1007/BF00308809 · DOI · Paper page
- Kim, 1990, Detection and quantification of β-peptide with two monoclonal antibodies, Neurosci Res Commun, 7, 113
Cited by
Items 801–900 of 963
Amyloid imaging in depression: a predictor of Alzheimer’s disease?
Camacho, V., & Lleó, A. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2741-7 · Cited by 1
Jauhiainen, A. M. (2008) · Cited by 1
Editorial: Brain-penetrant antibodies for Alzheimer’s disease: The next generation?
van Dyck, C. H. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100314 · Cited by 1
Role of Astrocytic Serine in Learning and Memory and its Implications in Alzheimer's Disease.
Maugard, M. (2018) · theses.fr (ABES) · doi:10.70675/2a0528d8zc687z43e6za9b4zfa45cdb5b6d9 · Cited by 4
Biomarkers for Alzheimer’s Disease and Frontotemporal Lobar Degeneration: Imaging
Bozzali, M., & Serra, L. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6380-0_10
The Role of Apolipoprotein E Concentration and Isoform in Amyloid-beta Metabolism In Vivo
Castellano, J. M. (2011) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7416v3s
“…compounds such as the [ 11 C]-benzothiazole radiotracer, Pittsburgh Compound B (PIB), brain amyloid in living subjects can be visualized and compared with other biomarkers of the disease and related to the clinical disease course (Ikonomovic et al., 2008; Klunk et al., 2004; Leinonen et al., 2008).”
BackgroundThe relationship between exercise and cognition in diabetes mellitus
Zhao, R. R. (2014) · The Sydney eScholarship Repository (The University of Sydney)
Imaging of the Geriatric Brain
Apostolova, L. G., Fleisher, A., Drzezga, A. E., Nair, A. K., & Sabbagh, M. N. (2014) · Wiley eBooks · doi:10.1002/9781118730676.ch7
Neuroimaging and Cognitive Assessments in early Drug Development
Cutler, N. R., Sramek, J. J., Murphy, M. F., Riordan, H., Bieck, P. R., & Carta, A. (2010) · Wiley eBooks · doi:10.1002/9781444318579.ch5
Amyloid imaging in Alzheimer´s disease and mild cognitive impairment by Positron Emission Tomography
Forsberg, A. (2008) · Figshare
Positron Emission Tomography and Neuroreceptor Mapping In Vivo
Lanzenberger, R. R., & Hahn, A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-397025-1.00018-x
Corlier, F. W. (2014) · theses.fr (ABES) · doi:10.70675/c68b852dz827az4d11z94a4z004c68a07153
“La mesure de rétention du PIB est également corrélée avec le dosage du peptide amyloïde dans le LCR (Ikonomovic et al., 2008; Sojkova et al., 2011; Lockhart et al., 2007).”
InfluentialBalasa, M. (2013) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
New Diagnostic Criteria for Alzheimer’s Disease
Dubois, B. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.12 · Cited by 1
Drzezga, A. E., & Perneczky, R. (2010) · The Open Nuclear Medicine Journal · doi:10.2174/1876388x01002010053
Almkvist, O., Kadir, A., & Nordberg, A. K. (2014) · Neurocase · doi:10.1080/13554794.2014.979835
“The second case (Ikonomovic et al., 2008) showed that PIB binding was selective to Aβ and not related to NFT.”
BackgroundResultAmyloidplaque-Bildgebung in der Demenzdiagnostik
Drzezga, A. E. (2009) · Der Nuklearmediziner · doi:10.1055/s-0028-1128137
Pittsburgh compound B as a marker of cognitive decline
Rinne, J. O. (2010) · Future Neurology · doi:10.2217/fnl.10.23
“Increased [C]PIB uptake detected by PET imaging correlated well with the volume of b-amyloid deposits in the brain, seen either at postmortem [16] or in vivo biopsy study [17].”
BackgroundDiagnosticare la malattia di Alzheimer
Sarazin, M., Hamelin, L., Lamari, F., & Bottlaender, M. (2014) · EMC - Neurologia · doi:10.1016/s1634-7072(14)67223-8
Computational Approaches for the Processing of Cerebral Histological Images of Small Animals
Dauguet, J. (2012) · Advances in intelligent and soft computing · doi:10.1007/978-3-642-25547-2_11
“validation of a AD PET marker, [20]).”
Sun, Y.-W., Liu, X., Langbaum, J. B. S., Venditti, J., Reiman, E. M., & Chen, K. (2009) · ICME International Conference on Complex Medical Engineering (CME) · doi:10.1109/iccme.2009.4906616
“binds to fibrillar aggregates of the Aβ peptide [2;3].”
BackgroundSPECIFIC AMYLOID-BETA OLIGOMERS IN HUMAN CEREBROSPINAL FLUID
Handoko, M. (2012) · University of Minnesota Digital Conservancy (University of Minnesota)
Pet Amyloid Imaging: Can Its Diagnostic Potential Be Effectively Realized in the clinic?
Fleisher, A., & Wolk, D. A. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.73
Klinischer Nutzen nuklearmedizinischer Verfahren in der Demenzdiagnostik
Drzezga, A. E. (2009) · Nervenheilkunde · doi:10.1055/s-0038-1627142
“[11C]PIB-Studien haben übereinstimmend belegen können, dass dieser Tracer sehr selektiv bei Amyloidpathologie im Gehirn bindet und im Gegensatz dazu zu vernachlässigende Affinitäten zu anderen Proteinablagerungen wie den Tangles, den Lewy-Körperchen oder der Ubiquitinpathologie aufweist (38, 50, 92).”
Terapia de los Sentidos como Tratamiento de la Agitación en Pacientes con la Enfermedad de Alzheimer
Ordóñez, R., & Joaquín, C. (2013) · USFQ Digital Repository (Universidad San Francisco de Quito)
Impact of the IWG/Dubois Criteria for Alzheimer’s Disease in Imaging Studies
Dubois, B., & Uspenskaya, O. (2014) · Springer eBooks · doi:10.1007/978-3-642-54307-4_13
Jacob, A. (2014) · Cureus · doi:10.7759/cureus.177
“have demonstrated the efficacy of using PiB PET amyloid imaging to concretely identify abnormalities in specific neuronal regions [8].”
BackgroundMom and me: Brain metabolism links Alzheimer disease to maternal genes
DHAWAN, V. M., & Eidelberg, D. (2009) · Neurology · doi:10.1212/01.wnl.0000341939.31303.32
Grachev, I. D. (2015) · Journal of Neurology & Stroke · doi:10.15406/jnsk.2015.02.00050
“Amyloid imaging tracers have been shown to label CAA well in postmortem tissue [12,51] and binding to CAA likely contributes to the in vivo signal [52].”
InfluentialE Deputy Editor: Dr J.A.J.M. Deckers E Editorial Board:
Aarnink, R., Beckett, J., Maniawski, P., Neitzel, U., Silfen, E., Zeitler, G., Zimmermann, W., & Highway, B. E. (2009)
Medline, A. (2013) · PubMed · Cited by 1
Kirkwood, C. M. (2015) · D-Scholarship@Pitt (University of Pittsburgh)
Functional imaging of Alzheimer's disease
Taler, V., & Saykin, A. J. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511782091.025
Price, J. C., Lopresti, B. J., & Villemagne, V. L. (2012) · Neuromethods · doi:10.1007/7657_2012_47
Self-citationTC e risco cognitivo Uma prospecção no idoso do Vale do Tejo
da Saúde, C. (2011)
Ramanan, V. K. (2014) · IUScholarWorks (Indiana University) · doi:10.7912/c2/1951
DEVELOPMENT OF MOLECULAR IMAGING PROBE FOR IN VIVO IMAGING MISFOLDED PROTEINS
Harada, R., Okamura, N., Furumoto, S., Yoshikawa, T., Kudo, Y., & Yanai, K. (2012) · Nano-Biomedical Engineering (Tohoku University Global COE Programme) · doi:10.1142/9781848169067_0029
Molecular imaging in dementia: journey to the end of the night
Villemagne, V. L. (2009)
Imaging mouse models of neurodegeneration using multi-parametric MRI
Holmes, H. (2015) · UCL Discovery (University College London)
Aberrant functionalconnectivity withinthe basal ganglia of patients with Parkinson3 sd isease
Rolinski, M., Griffanti, L., Szewczyk‐Królikowski, K., Wilcock, G. K., Filippini, N., Zamboni, G., & Mackay, C. E. (2015)
Novel statistical models for complex data structures
Li, J., & Huang, S. (2012)
VARIANCE OF THE AMYLOID BETA PEPTIDE AS A METRIC FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE
Beckett, C. (2016) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2016.161
Kim, E. E., Im, H., Lee, D. S., & Kang, K. W. (2016) · Springer eBooks · doi:10.1007/978-3-319-28652-5_3
Functional Neuroimaging in Late-Life Mood Disorders
Patel, M. J., Aizenstein, H. J., & Smith, G. S. (2013) · Oxford University Press eBooks · doi:10.1093/med/9780199796816.003.0034
Biomarkers and Neurodegenerative Diseases: Promising Inroads Toward a Distant Goal
Rubenstein, R. (2014) · CRC Press eBooks · doi:10.1201/b17644-19
Vemuri, P., Murray, M. E., & Jack, C. R. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410529-4.00010-3
Drzezga, A. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-30081-8_26 · Cited by 1
Noninvasive Detection of Misfolded Proteins in the Brain Using [11C]BF-227 PET
Okamura, N., Furumoto, S., Tashiro, M., Furukawa, K., Arai, H., Kudo, Y., & Yanai, K. (2013) · IGI Global eBooks · doi:10.4018/978-1-4666-3604-0.ch025
“PIB retention in the neocortical areas is correlated with the Aβ plaque load (Ikonomovic et al., 2008).”
BackgroundThe lived experience of dementia
Nurock, S. (2017) · doi:10.1201/9781315381572-11
Automated Extraction of Biomarkers for Alzheimer's Disease from Brain Magnetic Resonance Images
Wolz, R. (2011) · Spiral (Imperial College London) · doi:10.25560/6996 · Cited by 1
Jeppsson, F. (2016) · DiVA (Stockholm University)
Othonos, K. M., & Rahim, T. (2014)
Diagnostiquer la maladie d'Alzheimer
Sarazin, M., Hamelin, L., Lamari, F., & Bottlaender, M. (2013)
Imaging Amnestic Mild Cognitive Impairment: Neuroinflammation, Beta-amyloid and Glutathione
Knezevic, D. (2016) · TSpace (University of Toronto)
ERP-based Detection of Brain Pathology in Rat Models for Preclinical Alzheimer's Disease
Nouriziabari, S. B. (2016) · TSpace (University of Toronto)
Walker, J. M. (2013) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/42989
Imaging in Neurology Research III: Neurodegenerative Diseases
Endepols, H., & Neumaier, B. (2017) · Springer eBooks · doi:10.1007/978-3-319-42202-2_30
Philippi, N. (2017) · theses.fr (ABES) · doi:10.70675/00f7daaczc08az4dd6z88c0z32efacb0d014 · Cited by 1
“Les PET amyloïdes tels que le PiB (Pittsburg compound) mettent en évidence la pathologie amyloïde sous forme fibrillaire mais pas sous la forme de dépôts diffus ou solubles (Bacskai et al., 2007 ; Ikonomovic et al., 2008 ; Leinonen et al., 2008) et sa topographie lésionnelle.”
BackgroundDiagnosis of Alzheimer’s disease
Rosa‐Neto, P., Rowley, J., Leuzy, A., Mohades, S., Shin, M., Dauar, M. T., & Gauthier, S. G. (2012) · doi:10.2217/ebo.12.66
Biomarkers in dementia with Lewy bodies
Donaghy, P. C. (2016)
Modifiable risk factors moderate the relationship between amyloid and cognition in midlifePreprint
Clark, L. R., Koscik, R., Allison, S., Berman, S. E., Carlsson, C., Norton, D., Bendlin, B., Asthana, S., Betthauser, T., Christian, B., et al. (2017) · bioRxiv · doi:10.1101/229062
“…Alzheimer’s disease-related pathology are the PET imaging tracer [C11]Pittsburgh Compound B, which allows for imaging of amyloid deposition in vivo (Ikonomovic et al., 2008), and CSF levels of amyloid-beta 1-42, which are correlated with the formation of amyloid plaques in the brain (Strozyk et…”
Imaging of Brain Amyloid Load in Early Alzheimer’s Disease
Grimmer, T., & Perryman, J. G. (2018) · Neuromethods · doi:10.1007/978-1-4939-7674-4_9
Voevodskaya, O. (2018) · Figshare
The Association of Diabetes in the Onset of Dementia in the Elderly Population
Kumar, A., & Sıngh, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812019-4.00008-8
Klein, E. (2017) · Open Archive Toulouse Archive Ouverte (University of Toulouse) · Cited by 1
Calcagni, M. L., Feudo, V., & Triumbari, E. K. A. (2018) · Geriatric Care · doi:10.4081/gc.2018.7729
Calvo, M. A. (2017) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/29463
Amyloid-β PET Imaging in Aging and Dementia
Tolboom, N., Ossenkoppele, R., & van Berckel, B. N. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-01523-7_11 · Cited by 2
Shafiq, M. (2019) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7266
Posterior cortical atrophy—a heterogeneous syndrome : A case series
Conrad, J., Kremmyda, O., Högen, T., Brendel, M., Rominger, A., Levin, J., & Danek, A. (2019) · BORIS (University Library Bern) · doi:10.7892/boris.132424
Früherkennung der Alzheimer-Krankheit mit Biomarkern der Bildgebung oder aus dem Liquor
Grimmer, T. (2019) · Nervenheilkunde · doi:10.1055/a-0949-1367
“Amyloid-PET ist ein quantitativer Marker, der sehr eng mit der Dichte der histopathologisch gezählten Amyloid-Plaques korreliert [8, 9], und ist seit einigen Jahren als zugelassenes Diagnostikum mit kommerziellen Markern verfügbar.”
BackgroundDetection of amyloid aggregation in living systems
Broersen, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819132-3.00007-5
Potential of Blood- and CSF-Based Biomarkers for Alzheimer’s Disease Diagnostics
Goldwaser, E. L., & Nagele, R. G. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780190634230.003.0016
Dementia with Lewy Bodies with Pure Agraphia for Kanji (Japanese Morphograms)
Nishida, H., Hayashi, Y., Kobayashi, M., & Sakurai, T. (2020) · Internal Medicine · doi:10.2169/internalmedicine.4777-20
“Amyloid PET with Pittsburgh compound B allows for the in vivo visualization of the Aβ peptide accumulation, which is an important biomarker and useful tool for the diagnosis of AD (22-24).”
MethodFung, Y. L. (2020) · Minerva Access (University of Melbourne)
Genetic and functional studies of genes involved in the pathogenesis of Alzheimer's disease
Natunen, T. (2014) · UEF eRepo (University of Eastern Finland)
Huang, Y. H., Jia, H., & Bao, W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816475-4.00013-6 · Cited by 1
Sharma, M. J., & Callahan, B. L. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.041324
Les amyloïdoses : détection à l'aide de nanoparticules et propriétés optiques originales
Pansieri, J. (2017) · theses.fr (ABES) · doi:10.70675/0e785fbcz0be7z4c5fz8158zc5e08a3c8269 · Cited by 1
Modelling prognostic trajectories in Alzheimer’s disease
Giorgio, J. (2020) · Apollo (University of Cambridge) · doi:10.17863/cam.58841
Erratum for Dementia with Lewy Bodies with Pure Agraphia for Kanji (Japanese Morphograms)
Nishida, H., Hayashi, Y., Kobayashi, M., & Sakurai, T. (2021) · Internal Medicine · doi:10.2169/internalmedicine.e001-21
Sévigny-Dupont, P. (2020) · Papyrus : Institutional Repository (Université de Montréal) · doi:10.71781/19164
Regulation of neuronal voltagegated calcium channels via carbon monoxide and amyloid-β
Kaisis, E. (2021) · CentAUR (University of Reading) · doi:10.48683/1926.00099563
Etudes biologiques de nouveaux radiotraceurs pour l'imagerie moléculaire de la maladie d'Alzheimer
Garin, D. (2012) · theses.fr (ABES) · doi:10.70675/7261dcecz2ebbz4693z91f3zaa6f8d6ccedb
Amyloid imaging in alzheimer’s disease: A literature review
Saidlitz, P., Voisin, T., Vellas, B. J., Payoux, P., Gabelle, A., Formaglio, M., & Delrieu, J. (2014) · The journal of nutrition health & aging · doi:10.1007/s12603-014-0485-5 · Cited by 1
Current awareness in geriatric psychiatry
(2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1917
Saint‐Aubert, L. (2012) · Thèses en ligne de l'Université Toulouse III (Université Toulouse III)
de Haan, W. (2012) · Pure Amsterdam UMC · Cited by 1
Von symptombasierter Diagnostik hin zu einem biologischen Konzept
Bungenberg, J., Costa, A. S., & Reetz, K. (2022) · NeuroTransmitter · doi:10.1007/s15016-022-9371-2
Kim, E. E., Im, H., Lee, D. S., & Kang, K. W. (2016) · Springer eBooks · doi:10.1007/978-3-319-28652-5_2
Neurobiology of Lewy Body Dementias: Animal and Human Studies
Galvin, J. E., & Brás, J. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0055 · Cited by 2
Nordberg, A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-397025-1.00071-3
Metadata
- Authors
- Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., Debnath, M. L., Hope, C. E., Isanski, B. A., Hamilton, R. L., & DeKosky, S. T.
- Affiliations
- University of Pittsburgh (US)
- Corresponding author
- DeKosky, Steven T.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03-12
- Volume
- 131
- Issue
- 6
- Pages
- 1630-1645
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC2408940
- OpenAlex
- W2156981442
- Cited by
- 933
- References
- 66
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 29 · 2023: 25 · 2022: 33 · 2021: 42 · 2020: 44 · 2019: 56 · 2018: 51 · 2017: 46 · 2016: 58 · 2015: 57 · 2014: 82 · 2013: 81 · 2012: 79
- FWCI
- 47.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, public-domain)
- Funders
- U.S. Department of Energy (FG02-03ER63590, DE-FD02-03 ER63590, ER63590, DE-FD02-03)
- Alzheimer's Association (AG14449, TLL-01-3381)
- University of Pittsburgh (AG05133)
- National Institute for Health and Care Research
- National Institutes of Health (AG05133, AG025204, AG14449, AG025516)
- National Institute on Aging (AG 05-133, R01AG018402, P01AG025204, RF1AG025516, P50AG005133, P01AG014449, R01AG020226, AG025516, K02AG001039, P01 AG14449, P50-AG-05133, R37AG025516, R01AG025516)
- National Institute of Mental Health (R01MH070729, K01MH001976)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, amyloid plaques, Pittsburgh compound B, neurofibrillary tangles, tau protein, postmortem brain, amyloid-beta 42, Aβ40, vascular amyloid deposits, prefrontal cortex, temporal cortex, cerebellum
- MeSH terms
- Alzheimer Disease, Aniline Compounds, Autopsy, Brain, Carbon Radioisotopes, Enzyme-Linked Immunosorbent Assay, Female, Humans, Image Interpretation, Computer-Assisted, Immunohistochemistry, Magnetic Resonance Imaging, Middle Aged, Thiazoles, Reproducibility of Results, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.